secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001564590-22-028027
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Q2 net loss $72.5M; cash runway extended into 2025 on manufacturing move savings
--------------------------------------------------------------------------------

- Cash position $579.6M at June 30, 2022, down $167.3M from Dec 31, 2021.
- Q2 net loss $72.5M ($0.39 per share) vs net income $18.7M in Q2 2021.
- Expect cash runway into 2025; ~$100M cost savings from relocating manufacturing to Bothell, WA.
- Plan to file INDs in 2022 for SC291 and SG295; SC451 (type 1 diabetes) IND in 2023.
- Presented preclinical data showing survival of HIP pancreatic islet cells, cardiomyocytes, RPE cells in NHP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000156459022028027/0001564590-22-028027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000156459022028027/sana-8k_20220804.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-028027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer